Drug Search Results
More Filters [+]

Losmapimod

Alternative Names: losmapimod, gw856553, gw856553x, gs856553
Latest Update: 2024-03-28
Latest Update Note: News Article

Product Description

Mechanisms of Action: MAPK Inhibitor,Immunomodulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation:
Fast Track - Muscular Dystrophies|Muscular Dystrophy, Facioscapulohumeral
Orphan Drug - Muscular Dystrophies|Muscular Dystrophy, Facioscapulohumeral *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Losmapimod

Countries in Clinic: Canada, Denmark, France, Germany, Italy, Netherlands, Spain, United Kingdom, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 3: Muscular Dystrophy, Facioscapulohumeral

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

FSHD

P2

Active, not recruiting

Muscular Dystrophy, Facioscapulohumeral

2025-10-01

24%

FIS-002-2019 OLE

P2

Active, not recruiting

Muscular Dystrophy, Facioscapulohumeral

2025-10-01

24%

REACH

P3

Active, not recruiting

Muscular Dystrophy, Facioscapulohumeral

2024-10-01

42%

2022-000389-16

P3

Active, not recruiting

Muscular Dystrophy, Facioscapulohumeral

2024-09-30

Recent News Events